ERZEUGNISSE DER CHEMISCHEN INDUSTRIE UND VERWANDTER INDUSTRIEN > PHARMAZEUTISCHE ERZEUGNISSE > Menschliches Blut; tierisches Blut, zu therapeutischen, prophylaktischen oder diagnostischen Zwecken zubereitet; Antisera, andere Blutfraktionen und immunologische Erzeugnisse, auch modifiziert oder in einem biotechnologischen Verfahren hergestellt; Vaccine, Toxine, Kulturen von Mikroorganismen (ausgenommen Hefen) und ähnliche Erzeugnisse; Zellkulturen, auch verändert > Vaccine, Toxine, Kulturen von Mikroorganismen (ausgenommen Hefen) und ähnliche Erzeugnisse > Vaccine für die Humanmedizin > Vaccine gegen SARS-assoziierte Coronaviren (SARS-CoV-Spezies)
Synonyme
SARS-CoV vaccine, Vaccine against SARS-related coronaviruses, Human vaccine
Schlagwörter
SARS-CoV-Impfstoff · Impfstoff gegen SARS-assoziierte Coronaviren · Humanimpfstoff · Humanmedizin · SARS-CoV · SARS-CoV-Spezies · SARS-CoV species · espèce SARS-CoV
1. (A) Products (other than radioactive ores) answering to a description in heading 2844 or 2845 are to be classified in those headings and in no other heading of the Nomenclature. (B) Subject to paragraph (A) above, products answering to a description in heading 2843, 2846 or 2852 are to be classified in those headings and in no other heading of this Section. 2. Subject to Note 1 above, products classifiable in heading 3004, 3005, 3006, 3212, 3303, 3304, 3305, 3306, 3307, 3506, 3707 or 3808 by reason of being put up in measured doses or for retail sale are to be classified in those headings and in no other heading of the Nomenclature. 3. Goods put up in sets consisting of two or more separate constituents, some or all of which fall in this Section and are intended to be mixed together to obtain a product of Section VI or VII, are to be classified in the heading appropriate to that product, provided that the constituents are: (a) having regard to the manner in which they are put up, clearly identifiable as being intended for use together without first being repacked; (b) presented together; and (c) identifiable, whether by their nature or by the relative proportions in which they are present, as being complementary one to another.
Quelle: Europäische Kommission - Erläuterungen zur KN (ENKN) und HS-Anmerkungen.
€0
1.0B PST€0
2.5B PST+€0
€4.89/PST
(€3.5K/kg)€15.93/PST
(€7.5K/kg)3.586
KonzentriertBeschaffungspartner in Drittländern
| # | Partner | Wert (EUR) | kg | €/kg | Anteil | Vj. |
|---|---|---|---|---|---|---|
| 1 | 🇨🇭 Switzerland | €2.4B | 85Kt | €28.6K/kg | 49.8% | |
| 2 | 🇺🇸 United States | €1.5B | 436Kt | €3.4K/kg | 30.2% | |
| 3 | 🇮🇳 India | €626.9M | 540Kt | €1.2K/kg | 12.9% | |
| 4 | 🇿🇦 South Africa | €213.4M | 253Kt | €843.67/kg | 4.4% | |
| 5 | 🇯🇵 Japan | €122.5M | 17Kt | €7.2K/kg | 2.5% | |
| 6 | 🇬🇧 United Kingdom | €9.6M | 623 | €15.4K/kg | 0.2% | |
| 7 | 🇬🇹 GT | €418K | 23 | €18.2K/kg | 0.0% |
Zielmärkte in Drittländern
| # | Partner | Wert (EUR) | kg | €/kg | Anteil | Vj. |
|---|---|---|---|---|---|---|
| 1 | 🇯🇵 Japan | €9.5B | 658Kt | €14.5K/kg | 34.7% | |
| 2 | 🇺🇸 United States | €8.9B | 2.3Mt | €3.8K/kg | 32.5% | |
| 3 | 🇬🇧 United Kingdom | €4.1B | 221Kt | €18.6K/kg | 15.0% | |
| 4 | 🇧🇷 Brazil | €2.8B | 209Kt | €13.3K/kg | 10.2% | |
| 5 | 🇦🇺 Australia | €1.9B | 140Kt | €13.9K/kg | 7.1% | |
| 6 | 🇲🇽 Mexico | €135.7M | 52Kt | €2.6K/kg | 0.5% |